**Core Concept:** Pulmonary hypertension is a condition characterized by increased blood pressure in the pulmonary circulation (arteries supplying the lungs). It can be caused by various factors such as heart, lung, or systemic diseases.

**Why the Correct Answer is Right:** Oxygen-rich blood from the heart is circulated through the pulmonary circulation, which includes the pulmonary artery, pulmonary veins, and the pulmonary capillaries. In pulmonary hypertension, the pulmonary vascular resistance increases, leading to elevated pulmonary arterial pressure and reduced blood flow to the lungs. The correct answer, **Diltiazem**, is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle cells. This results in vasodilation of pulmonary vessels, decreasing pulmonary vascular resistance and thus lowering pulmonary arterial pressure.

**Why Each Wrong Option is Incorrect:**

A. **Nitroglycerin:** Nitroglycerin is a nitric oxide donor, causing systemic vasodilation and reducing preload (fluid volume in the heart chambers), which is not specific to the pulmonary circulation.

B. **Inhaled bronchodilators:** Inhaled bronchodilators (e.g., salbutamol) primarily relax smooth muscle in the airways of the lungs, not the pulmonary vasculature.

C. **Sildenafil:** Sildenafil is a phosphodiesterase type 5 inhibitor, which causes pulmonary vasodilation and improves oxygenation in pulmonary arterial hypertension. However, it is not a treatment for pulmonary hypertension caused by increased pulmonary vascular resistance.

**Clinical Pearl:** Pulmonary hypertension has several etiologies, and treatment options depend on the underlying cause. Oxygen therapy, diuretics, and vasodilators are some of the management strategies. In cases of pulmonary arterial hypertension, pulmonary vasodilators like sildenafil may be used, while in cases of increased pulmonary vascular resistance, calcium channel blockers like diltiazem are beneficial.

**Correct Answer Explanation:** Diltiazem is a calcium channel blocker that targets pulmonary vasculature and reduces pulmonary vascular resistance, providing relief to patients suffering from pulmonary hypertension due to increased pulmonary vascular resistance.